These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 7531216

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC, Golden AM, Lund JK, Gürtler LG, Zekeng L, Obiang J, Kaptué L, Hampl H, Vallari A, Devare SG.
    AIDS Res Hum Retroviruses; 1997 Aug 10; 13(12):995-1005. PubMed ID: 9264286
    [Abstract] [Full Text] [Related]

  • 3. Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france.
    Damond F, Apetrei C, Robertson DL, Souquière S, Leprêtre A, Matheron S, Plantier JC, Brun-Vézinet F, Simon F.
    Virology; 2001 Feb 01; 280(1):19-30. PubMed ID: 11162815
    [Abstract] [Full Text] [Related]

  • 4. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE.
    J Virol; 2005 Jun 01; 79(11):6957-68. PubMed ID: 15890935
    [Abstract] [Full Text] [Related]

  • 5. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L, Zolla-Pazner S, Gorny MK, Cheng-Mayer C.
    Virology; 1997 Mar 17; 229(2):360-9. PubMed ID: 9126249
    [Abstract] [Full Text] [Related]

  • 6. Molecular analyses of HIV-1 group O and HIV-2 variants from Africa.
    Hunt JC, Brennan CA, Golden AM, Yamaguchi J, Lund JK, Vallari AS, Hickman RK, Zekeng L, Gürtler LG, Hampl H, Kaptué L, Devare SG.
    Leukemia; 1997 Apr 17; 11 Suppl 3():138-41. PubMed ID: 9209322
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.
    Björling E, Chiodi F, Utter G, Norrby E.
    J Immunol; 1994 Feb 15; 152(4):1952-9. PubMed ID: 8120399
    [Abstract] [Full Text] [Related]

  • 9. Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes.
    Chang SY, Vithayasai V, Vithayasai P, Essex M, Lee TH.
    J Infect Dis; 2000 Aug 15; 182(2):442-50. PubMed ID: 10915074
    [Abstract] [Full Text] [Related]

  • 10. Antigenic variation of SIV: mutations in V4 alter the neutralization profile.
    Kinsey NE, Anderson MG, Unangst TJ, Joag SV, Narayan O, Zink MC, Clements JE.
    Virology; 1996 Jul 01; 221(1):14-21. PubMed ID: 8661410
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from guinea-bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa.
    Andersson S, Norrgren H, Dias F, Biberfeld G, Albert J.
    Virology; 1999 Sep 30; 262(2):312-20. PubMed ID: 10502510
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 30; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G.
    J Med Virol; 2000 Sep 30; 62(1):14-24. PubMed ID: 10935983
    [Abstract] [Full Text] [Related]

  • 18. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
    McKeating JA, Zhang YJ, Arnold C, Frederiksson R, Fenyö EM, Balfe P.
    Virology; 1996 Jun 15; 220(2):450-60. PubMed ID: 8661395
    [Abstract] [Full Text] [Related]

  • 19. The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them.
    Nyambi PN, Willems B, Janssens W, Fransen K, Nkengasong J, Peeters M, Vereecken K, Heyndrickx L, Piot P, van der Groen G.
    AIDS Res Hum Retroviruses; 1997 Jan 01; 13(1):7-17. PubMed ID: 8989422
    [Abstract] [Full Text] [Related]

  • 20. Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein.
    Kent KA.
    J Med Primatol; 1995 May 01; 24(3):145-9. PubMed ID: 8751054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.